Review key data that support use of concurrent chemoradiotherapy with cisplatin plus etoposide as standard of care for LS-SCLC.
Gain expert insight on the biologic rationale for using immune checkpoint inhibition for the treatment of ES-SCLC, including the potential for synergism between immunotherapy and platinum-based chemotherapy.
Watch this short video evaluating key clinical trial data supporting use of first-line immune checkpoint inhibitors plus chemotherapy in the treatment of newly diagnosed ES-SCLC.
Watch this short video discussing current best practices for treating a patient with newly diagnosed extensive-stage SCLC.
View this short video evaluating the clinical trial data for second-line and third-line treatment options for relapsed ES-SCLC.
Watch this short case-based video for an overview of the evolving systemic therapy options for the treatment of relapsed ES-SCLC.
Watch this short video on early recognition and management of immune-related adverse events from immunotherapy for the treatment of ES-SCLC in the context of a patient case.
Watch this short video to get up to date on the role of prophylactic cranial irradiation and consolidative thoracic radiotherapy in the treatment of ES-SCLC.
Watch this short video to get up to date on the role of biomarkers in predicting benefit of immune checkpoint blockade during treatment of extensive-stage SCLC.
Watch this short video for an expert review of key ongoing trials of immune checkpoint inhibitor combinations for SCLC to consider for your patients, including ADRIATIC and NRG-LU005 for limited-stage disease and SKYSCRAPER-02 for extensive-stage disease.